A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL
Graham P. Collins(Churchill Hospital), Dima El‐Sharkawi(Royal Marsden Hospital), Ahmed Abdulgawad(The Christie NHS Foundation Trust), Ruth Plummer(National Health Service), George W. Cole(Nurix (United States)), Anja Williams(Sarah Cannon Research Institute), Sarah P. Blagden(Churchill Hospital), Adam Sharp(Institute of Cancer Research), William Townsend(University College Hospital), Matthew Krebs(Christie's), Daniel Hochhauser(Royal London Hospital), JEFF EVANS(University of Glasgow), Ana Filipa Palma DosReis(University of Cambridge), Swathi Namburi(MultiCare Tacoma General Hospital), Daniel Chan(Sanford Research), Seema Rogers(Nurix (United States)), Sarah Whelan(Nurix (United States))
Cited by 9
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537